John Latham - Alder BioPharmaceutica Co-Founder and Chief Scientific Officer

Founder

Dr. John A. Latham, Ph.D., is Chief Scientific Officer of the Company. Dr. Latham served as a director, senior director, and most recently as Vice President of Gene Function and Target Validation for Celltech Group plc. In 1994, Dr. Latham joined Darwin Molecular Corporationrationration, a firstgeneration genetodrug biotechnology company, as a founding director, where he served from 1994 to 1998. Dr. Latham was one of the early scientists hired by Gilead Sciences, Inc., a biopharmaceutical company, and, from 1989 to 1994, he was a member of a core group established to exploit novel oligonucleotidebased technologies
Age 57
Professional MarksPh.D
Phone425 205-2900
Webwww.alderbio.com
Latham holds a Ph.D. in Biochemistry from Massachusetts Institute of Technology and a B.S. in Chemistry from Colorado State University.

Alder BioPharmaceutica Management Efficiency

The company has return on total asset (ROA) of (100.8551) % which means that it has lost $100.8551 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4193) %, meaning that it created substantial loss on money invested by shareholders. Alder BioPharmaceutica's management efficiency ratios could be used to measure how well Alder BioPharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 193.36 M in liabilities with Debt to Equity (D/E) ratio of 89.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Alder BioPharmaceuticals has a current ratio of 8.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Alder BioPharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Alder BioPharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alder BioPharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alder to invest in growth at high rates of return. When we think about Alder BioPharmaceutica's use of debt, we should always consider it together with cash and equity.
Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington. Alder BioPharmaceutica operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 202 people. Alder BioPharmaceuticals (ALDR) is traded on NASDAQ Exchange in USA and employs 202 people.

Management Performance

Alder BioPharmaceuticals Leadership Team

Elected by the shareholders, the Alder BioPharmaceutica's board of directors comprises two types of representatives: Alder BioPharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alder. The board's role is to monitor Alder BioPharmaceutica's management team and ensure that shareholders' interests are well served. Alder BioPharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alder BioPharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
Erin Lavelle, COO
Xavier GallotLavallee, Member of the Supervisory Board
Deepa Pakianathan, Independent Director
Bruce Montgomery, Independent Director
Paul Streck, Chief Medical Officer
Anne TrotouxCoppermann, Member of the Supervisory Board
Robert Azelby, President CEO
Christian Viguie, Chairman of the Supervisory Board
Deepika Pakianathan, Independent Director
John Latham, Co-Founder and Chief Scientific Officer
Jeremy Green, Director
Bruno Pavlovsky, Member of the Supervisory Board
Wendy Yarno, Independent Director
Joel Desmaris, Member of the Management Board in Charge of Finance and Investor Relations
Olivier Lambert, Member of the Supervisory Board
Randal Hassler, Senior Vice President Pharmaceutical Operations
Paul Carter, Director
Stephen Dow, Independent Chairman of the Board
Randall Schatzman, Co-Founder, CEO and President and Director
Eric Carter, Interim Chief Medical Officer
Nadia Dac, Chief Commercial Officer
Mark Litton, Chief Business Officer, Treasurer and Secretary
Larry Benedict, Sr. VP of Fin.
Carlos Campoy, CFO
Pierre Conte, Member of the Supervisory Board
Pierre Tourrette, Vice Chairman of the Supervisory Board
Heather Preston, Independent Director
Jeffrey Smith, Senior Vice President Translational Medicine
Timothy Whitaker, Chief Medical Officer
James Bucher, Senior Vice President General Counsel
Paul Cleveland, Director
Clay Siegall, Independent Director
Frederic Serre, Chairman of the Management Board
Elisabeth Sandoval, Chief Commercial Officer
Philippe Mattia, Member of the Supervisory Board

Alder Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alder BioPharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alder BioPharmaceutica in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alder BioPharmaceutica's short interest history, or implied volatility extrapolated from Alder BioPharmaceutica options trading.

Pair Trading with Alder BioPharmaceutica

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alder BioPharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alder BioPharmaceutica will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to GameStop Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GameStop Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GameStop Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GameStop Corp to buy it.
The correlation of GameStop Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GameStop Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GameStop Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GameStop Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Alder BioPharmaceuticals information on this page should be used as a complementary analysis to other Alder BioPharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Other Consideration for investing in Alder Stock

If you are still planning to invest in Alder BioPharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alder BioPharmaceutica's history and understand the potential risks before investing.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years